Kidney involvement in COVID-19 and rationale for extracorporeal therapies

Claudio Ronco; Thiago Reis

doi:10.1038/s41581-020-0284-7

Kidney involvement in COVID-19 and rationale for extracorporeal therapies

Nat Rev Nephrol. 2020 Jun;16(6):308-310. doi: 10.1038/s41581-020-0284-7.

Authors

Claudio Ronco^{1

2}, Thiago Reis^{3

4}

Affiliations

¹ Department of Medicine (DIMED), University of Padova, Padova, Italy. cronco@goldnet.it.
² Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza, San Bortolo Hospital, Vicenza, Italy. cronco@goldnet.it.
³ Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza, San Bortolo Hospital, Vicenza, Italy.
⁴ Department of Nephrology, Clinica de Doenças Renais de Brasilia, Brasilia, Brazil.

Abstract

The prevalence of direct kidney involvement in novel coronavirus disease (COVID-19) is low, but such involvement is a marker of multiple organ dysfunction and severe disease. Here, we explore potential pathways of kidney damage and discuss the rationale for extracorporeal support with various blood purification strategies in patients who are critically ill with COVID-19.

MeSH terms

Acute Kidney Injury / physiopathology
Acute Kidney Injury / virology*
Betacoronavirus*
COVID-19
Coronavirus Infections / complications*
Coronavirus Infections / immunology
Coronavirus Infections / therapy
Cytokines / immunology
Humans
Kidney Function Tests
Pandemics
Pneumonia, Viral / complications*
Pneumonia, Viral / immunology
Pneumonia, Viral / therapy
SARS-CoV-2

Substances

Cytokines